Buprenorphine has been used internationally for the treatment of opioid use disorder (OUD)
since the 1990s and has been available in the United States for more than a decade. Initial …

Abstract Purpose of Review The rising prevalence of opioid use disorder (OUD) and related
complications in North America coupled with limited numbers of specialists in addiction …

Background Medications for opioid use disorder (MOUD; methadone, buprenorphine,
naltrexone) are the most effective treatments for OUD, and MOUD is protective against fatal …

Background Although buprenorphine is an evidence-based treatment for opioid use
disorder (OUD), many individuals discontinue treatment soon after starting. This study …

Background Buprenorphine is abused in several countries notwithstanding its benefits as an
analgesic and as an opioid agonist treatment medication. Benzodiazepines and alcohol …

A tremendous treatment gap exists for the care of persons with opioid use disorder. The vast
majority of waivered practitioners, more than 90%, are in urban United States counties. The …

Introduction Concurrent prescribing of opioids and benzodiazepines is discouraged by
evidence-based clinical guidelines because of the known risks of taking these medications …

Background Due to the loss of tolerance to opioids during medication-assisted treatment
(MAT), this period may represent a time of heightened risk for overdose. Identifying factors …

Introduction Prescription opioid use in Australia has increased over the last 3 decades. The
majority of opioids are prescribed and dispensed in primary care, however, there are few …

Abstract Introduction Gabapentinoids (GABAs) and serotonergic drugs (selective serotonin
reuptake inhibitors [SSRIs]/serotonin and norepinephrine reuptake inhibitors [SNRIs]) are …